Drug Profile
Research programme: antibody drug conjugates - Centre for the Commercialization of Antibodies and Biologics/ImmunoBiochem Corporation
Alternative Names: IMB-101; IMB-102; IMB-202; IMB-212Latest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Centre for the Commercialization of Antibodies and Biologics; ImmunoBiochem
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Solid-tumours in Canada (Parenteral)
- 18 Apr 2016 ImmunoBiochem Corporation and Centre for the Commercialization of Antibodies and Biologics (CCAB) agree to co-develop antibody-drug conjugates in Canada for Breast cancer and Solid tumours
- 18 Apr 2016 Preclinical trials in Solid tumours in Canada (Parenteral)